Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours

Affiliations

• ¹ Clinical Lead, Dept of Nuclear Medicine, Auckland DHB and Honorary Senior Lecturer, Department of Imaging, University of Auckland, New Zealand.
• ² Clinical Nurse Specialist, Oncology, BHScNursing, PGDip, Auckland District Health Board, New Zealand.
• ³ Team Leader, Department of Nuclear Medicine, Auckland DHB, New Zealand.
• ⁴ Medical Physicist, Health Physics Services Ltd, New Zealand.
• ⁵ Medical Physicist, Department of Oncology, Auckland DHB, New Zealand.